Azithromycin and Rifampin

Phase 3Small molecule

UUniversity of South Florida

Azithromycin and Rifampin is one of 7 small molecule programs targeting Reactive Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Reactive ArthritisActive, not recruiting

Reactive ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Reactive Arthritis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Approved

—2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Remicade

1 5

Actimmune

HHorizon Therapeutics Ireland DAC

Interferon-Gamma

1 7

Azithromycin and Rifampin

UUniversity of South Florida

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Reactive Arthritis1 trial

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Completed·UUniversity of South Florida·Phase 3·NCT00351273·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azithromycin and Rifampin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azithromycin and Rifampin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azithromycin and Rifampin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of South Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of South Florida

Azithromycin and Rifampin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Reactive Arthritis1 trial

References

Drug Info

Quick Facts

Related News